Buchholz
TL2 Member · Pisa, IT
Here for the documentation. Occasionally files a wiki request when a page has drifted out of date.
Joined 6 May 2025 · last posted 1d
90Posts here
5Topics
0Solutions
1.1kLikes received
1.9kLikes given
22Badges
235Days visited
4.5kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Documenting an adverse event properly Replied, post #23 · Safety › Adverse events · 27 Jul 2026 · 5 likes Allergic reactions: true allergy (anaphylaxis, severe rash) is rare with these peptide compounds but possible. Distinguishing true allergy from GI intolerance matters.
-
Seven-day rolling means and why weekly readings mislead Replied, post #113 · Outcomes › Progress reports · 26 Jul 2026 · 19 likes On post #109 — agreed on the reasoning, with one qualification. Two things before anyone answers the substance. First, the context in the first post is clear and…
-
CJC-1295 with and without DAC: what the modification does Replied, post #119 · Compounds › Secretagogues & GH axis · 22 Jul 2026 · 3 likes post #118 answers the question as asked. The question underneath it is different. Reading a rodent study on a secretagogue without over-extrapolating: rodent studies…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #80 · Practice › Dosing & titration · 20 Jul 2026 · 0 likes Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #87 · Start Here › Welcome · 16 Jul 2026 · 1 like Marked solutions are the site's way of saying that someone asked a good question and someone else gave an answer that actually worked. It is not a competition and it…
-
Follow-up: The retatrutide phase 2 obesity paper, read closely Replied, post #22 · Compounds › Retatrutide · 13 Jul 2026 · 0 likes What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate…
-
Forced degradation studies: designing one that is informative Replied, post #94 · Analytics › Method validation · 9 Jul 2026 · 10 likes post #93 is right about the mechanism and I think understates the practical bit. Stability-indicating method: one that can separate a compound from its degradation…
-
Journal club: STEP 1 and the treatment-policy estimand Replied, post #2 · Evidence › Journal club · 8 Jul 2026 · 0 likes SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological endpoint. Notable because soft endpoints are avoided. Two…
-
Why this subcategory is stricter about sourcing than most Replied, post #48 · Compounds › Secretagogues & GH axis · 26 Jun 2026 · 20 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Review: a draft on reconstitution arithmetic, with objections — what changed since Replied, post #30 · Documentation › Doc review · 26 Jun 2026 · 0 likes Coming back to post #28, because the follow-up matters more than the original answer. Citation checking: if a maintained page cites a paper, the citation should match…
-
Search filters: what is missing Replied, post #70 · Meta › Site feedback · 17 Jun 2026 · 0 likes This follows post #67 rather than contradicting it. Guideline clarity: if the guidelines are unclear or seem to be applied inconsistently, post the specific situation…
-
Why the timeline is on the right and not the left — what changed since Replied, post #56 · Meta › Site feedback · 17 Jun 2026 · 2 likes Worth separating two things that post #52 runs together. Accessibility: screen readers, keyboard navigation, contrast, font size — if something is not accessible to…